PT3359564T - Anticorpos que neutralizam de um modo potente o vírus da hepatite b e as suas utilizações - Google Patents
Anticorpos que neutralizam de um modo potente o vírus da hepatite b e as suas utilizaçõesInfo
- Publication number
- PT3359564T PT3359564T PT167790757T PT16779075T PT3359564T PT 3359564 T PT3359564 T PT 3359564T PT 167790757 T PT167790757 T PT 167790757T PT 16779075 T PT16779075 T PT 16779075T PT 3359564 T PT3359564 T PT 3359564T
- Authority
- PT
- Portugal
- Prior art keywords
- antibodies
- virus
- potently neutralize
- neutralize hepatitis
- hepatitis
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/081—DNA viruses
- C07K16/082—Hepadnaviridae (F), e.g. hepatitis B virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Gastroenterology & Hepatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2015/001970 WO2017059878A1 (en) | 2015-10-07 | 2015-10-07 | Antibodies that potently neutralize hepatitis b virus and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT3359564T true PT3359564T (pt) | 2020-09-04 |
Family
ID=54330711
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT167790757T PT3359564T (pt) | 2015-10-07 | 2016-10-07 | Anticorpos que neutralizam de um modo potente o vírus da hepatite b e as suas utilizações |
Country Status (24)
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017059878A1 (en) * | 2015-10-07 | 2017-04-13 | Humabs Biomed Sa | Antibodies that potently neutralize hepatitis b virus and uses thereof |
| EP4389222A3 (en) | 2018-05-10 | 2024-08-28 | Melbourne Health | Methods and compositions for the treatment of hepatitis b infection |
| WO2019222506A1 (en) * | 2018-05-16 | 2019-11-21 | Chang Gung Memorial Hospital, Linkou | Novel leucine-rich repeat neuronal protein 1 (lrrn1) antibodies and uses thereof |
| CN119490583A (zh) | 2018-05-31 | 2025-02-21 | 诺华股份有限公司 | 乙型肝炎抗体 |
| CA3121247A1 (en) | 2018-12-03 | 2020-06-11 | Board Of Regents, The University Of Texas System | Oligo-benzamide analogs and their use in cancer treatment |
| SI3898668T1 (sl) * | 2018-12-19 | 2024-02-29 | Humabs Biomed Sa | Protitelesa, ki nevtralizirajo virus hepatitisa B in njihove uporabe |
| PT4285929T (pt) * | 2018-12-20 | 2026-01-02 | Humabs Biomed Sa | Terapêutica de combinação contra o vhb |
| KR102084912B1 (ko) * | 2019-01-17 | 2020-03-05 | 주식회사 녹십자 | B형 간염 바이러스 표면 항원의 입체 에피토프 및 이에 특이적으로 결합하는 항체 |
| US12509504B2 (en) | 2019-07-20 | 2025-12-30 | Huahui Health Ltd. | Method of treating HBV infection by using anti-pre-S1 HBV antibodies |
| US20220380441A1 (en) * | 2019-08-29 | 2022-12-01 | Vir Biotechnology, Inc. | Antibody compositions and methods for treating hepatitis b virus infection |
| CN114728066B (zh) * | 2019-09-11 | 2026-06-16 | 洛克菲勒大学 | 与乙型肝炎的人中和抗体相关的组合物和方法 |
| CN113717283B (zh) * | 2020-05-25 | 2023-05-26 | 厦门万泰凯瑞生物技术有限公司 | 一种抗乙型肝炎病毒e抗原的单克隆抗体及其应用 |
| US20250085288A1 (en) * | 2020-06-02 | 2025-03-13 | Rcmg Inc. | Anti-rna virus particle antibody of hbv |
| CA3184495A1 (en) * | 2020-06-08 | 2021-12-16 | F. Hoffmann-La Roche Ag | Anti-hbv antibodies and methods of use |
| EP4168547A1 (en) * | 2020-06-22 | 2023-04-26 | Janssen Pharmaceuticals, Inc. | Compositions and methods for treatment of hepatitis d virus infection |
| BR112022026316A2 (pt) | 2020-06-24 | 2023-03-07 | Vir Biotechnology Inc | Anticorpos neutralizantes do vírus da hepatite b engenheirados e usos dos mesmos |
| TWI868379B (zh) * | 2020-07-09 | 2025-01-01 | 大陸商北京凱因科技股份有限公司 | 結合ｂ型肝炎病毒表面抗原的抗體及其應用 |
| TWI815194B (zh) | 2020-10-22 | 2023-09-11 | 美商基利科學股份有限公司 | 介白素2-Fc融合蛋白及使用方法 |
| JP2024504167A (ja) | 2021-01-26 | 2024-01-30 | ヴィア・バイオテクノロジー・インコーポレイテッド | Ｂ型肝炎ウイルス感染を処置するための抗体組成物および方法 |
| CN113234144B (zh) * | 2021-05-26 | 2022-02-25 | 武汉工程大学 | 一种人源性抗乙肝表面抗原的单链抗体、制剂、编码基因、载体质粒及宿主细胞 |
| WO2023287352A2 (en) * | 2021-07-15 | 2023-01-19 | National University Of Singapore | Anti-hbv antibodies and uses thereof |
| CN113777312B (zh) * | 2021-09-03 | 2024-02-02 | 普十生物科技(北京)有限公司 | 乙肝抗体片段的制备方法、乙肝抗体片段、试剂盒及应用 |
| WO2023039243A2 (en) * | 2021-09-13 | 2023-03-16 | Achelois Biopharma, Inc. | Hepatitis b virus antivirus (hbv-antivirus) compositions and methods of use |
| CA3242060A1 (en) * | 2021-12-21 | 2023-06-29 | Hbvtech, Llc. | Methods for eliminating hepatitis b virus cccdna and rcdna and the hepatitis b drugs used in the methods thereof |
| WO2023230439A1 (en) | 2022-05-23 | 2023-11-30 | Vir Biotechnology, Inc. | Fc-engineered hepatitis b virus neutralizing antibodies and uses thereof |
| CN116162153B (zh) * | 2022-09-01 | 2024-09-10 | 复旦大学附属中山医院 | 一种乙肝病毒表面抗原的单克隆抗体及其应用 |
| CN118725092B (zh) * | 2023-03-28 | 2025-08-12 | 东莞市朋志生物科技有限公司 | 抗HBs-Ag抗体、检测HBs-Ag的试剂和试剂盒 |
| IL324645A (en) * | 2023-05-31 | 2026-01-01 | Bluejay Therapeutics Inc | Anti-HBsAg antibody for the treatment of chronic hepatitis D |
| CN119143869A (zh) * | 2023-06-16 | 2024-12-17 | 复旦大学 | 乙肝病毒表面抗体及其应用 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL154600B (nl) | 1971-02-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen. |
| US3817837A (en) | 1971-05-14 | 1974-06-18 | Syva Corp | Enzyme amplification assay |
| US3766162A (en) | 1971-08-24 | 1973-10-16 | Hoffmann La Roche | Barbituric acid antigens and antibodies specific therefor |
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| US4233402A (en) | 1978-04-05 | 1980-11-11 | Syva Company | Reagents and method employing channeling |
| JPS5896026A (ja) | 1981-10-30 | 1983-06-07 | Nippon Chemiphar Co Ltd | 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤 |
| US4609546A (en) | 1982-06-24 | 1986-09-02 | Japan Chemical Research Co., Ltd. | Long-acting composition |
| US4766106A (en) | 1985-06-26 | 1988-08-23 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| US4831175A (en) | 1986-09-05 | 1989-05-16 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Backbone polysubstituted chelates for forming a metal chelate-protein conjugate |
| US5595721A (en) | 1993-09-16 | 1997-01-21 | Coulter Pharmaceutical, Inc. | Radioimmunotherapy of lymphoma using anti-CD20 |
| CA2251904A1 (en) | 1996-04-18 | 1997-10-23 | Abbott Laboratories | An antigenic epitope of the a determinant of hepatitis b surface antigen and uses thereof |
| GB9608626D0 (en) * | 1996-04-25 | 1996-07-03 | Univ College Of London | Hepatitis b monoclonal antibodies |
| WO1998029442A1 (en) * | 1996-12-30 | 1998-07-09 | Innogenetics N.V. | ANNEXIN V-BINDING POLYPEPTIDES DERIVED FROM HBsAg AND THEIR USES |
| MY133346A (en) | 1999-03-01 | 2007-11-30 | Biogen Inc | Kit for radiolabeling ligands with yttrium-90 |
| US20020102208A1 (en) | 1999-03-01 | 2002-08-01 | Paul Chinn | Radiolabeling kit and binding assay |
| WO2004076677A2 (en) | 2003-02-26 | 2004-09-10 | Institute For Research In Biomedicine | Monoclonal antibody production by ebv transformation of b cells |
| US7700097B2 (en) | 2003-06-27 | 2010-04-20 | Biogen Idec Ma Inc. | Purification and preferential synthesis of binding molecules |
| CA2594922A1 (en) * | 2005-01-14 | 2006-07-20 | The Government Of The United States Of America, As Represented By The Se Cretary, Department Of Health And Human Services | Monoclonal antibodies that bind or neutralize hepatitis b virus |
| MX2009012343A (es) | 2007-05-14 | 2010-02-10 | Biogen Idec Inc | Regiones fc (sc fc) de cadena sencilla, polipeptidos de enlace que comprenden las mismas, y metodos relacionados con ello. |
| KR20090056537A (ko) * | 2007-11-30 | 2009-06-03 | 주식회사 녹십자 | Ｂ형 간염 바이러스 중화능을 갖는 항체를 유효성분으로포함하는 ｂ형 간염 바이러스 감염의 예방 또는 치료용조성물 |
| ES2525346T3 (es) | 2008-10-22 | 2014-12-22 | Institute For Research In Biomedicine | Métodos para producir anticuerpos a partir de células plasmáticas |
| CN104837501B (zh) * | 2012-08-30 | 2018-11-02 | 里普利科股份有限公司 | 治疗乙型肝炎及丁型肝炎感染的方法 |
| JP6445447B2 (ja) | 2012-11-12 | 2018-12-26 | ルプレヒト−カールス−ウニヴェルジテート ハイデルベルクＲｕｐｒｅｃｈｔ−Ｋａｒｌｓ−Ｕｎｉｖｅｒｓｉｔａｅｔ Ｈｅｉｄｅｌｂｅｒｇ | Ｈｂｖ及び／又はｈｄｖ感受性の細胞、細胞株及び非ヒト動物の開発 |
| SG10201806025TA (en) * | 2014-01-16 | 2018-08-30 | Mario Umberto Francesco Mondelli | Neutralizing human monoclonal antibodies against hepatitis b virus surface antigen |
| WO2017059878A1 (en) * | 2015-10-07 | 2017-04-13 | Humabs Biomed Sa | Antibodies that potently neutralize hepatitis b virus and uses thereof |
-
2015
- 2015-10-07 WO PCT/EP2015/001970 patent/WO2017059878A1/en not_active Ceased
-
2016
- 2016-10-07 DK DK16779075.7T patent/DK3359564T3/da active
- 2016-10-07 EP EP20177206.8A patent/EP3753949A1/en active Pending
- 2016-10-07 MY MYPI2018700678A patent/MY187161A/en unknown
- 2016-10-07 CN CN201680055161.8A patent/CN108137675B/zh active Active
- 2016-10-07 BR BR112018002406-6A patent/BR112018002406A2/pt not_active Application Discontinuation
- 2016-10-07 CA CA2993745A patent/CA2993745A1/en active Pending
- 2016-10-07 LT LTEP16779075.7T patent/LT3359564T/lt unknown
- 2016-10-07 HU HUE16779075A patent/HUE050231T2/hu unknown
- 2016-10-07 EP EP16779075.7A patent/EP3359564B1/en active Active
- 2016-10-07 US US15/766,703 patent/US10683344B2/en active Active
- 2016-10-07 KR KR1020187012979A patent/KR102725168B1/ko active Active
- 2016-10-07 HR HRP20201345TT patent/HRP20201345T1/hr unknown
- 2016-10-07 AU AU2016334735A patent/AU2016334735B2/en active Active
- 2016-10-07 CN CN202210185497.3A patent/CN114539391A/zh active Pending
- 2016-10-07 WO PCT/EP2016/074114 patent/WO2017060504A1/en not_active Ceased
- 2016-10-07 PT PT167790757T patent/PT3359564T/pt unknown
- 2016-10-07 MX MX2018004127A patent/MX2018004127A/es unknown
- 2016-10-07 SI SI201630896T patent/SI3359564T1/sl unknown
- 2016-10-07 ES ES16779075T patent/ES2813927T3/es active Active
- 2016-10-07 JP JP2018514962A patent/JP6869968B2/ja active Active
- 2016-10-07 EA EA201890874A patent/EA038301B1/ru unknown
- 2016-10-07 PL PL16779075T patent/PL3359564T3/pl unknown
- 2016-10-07 CN CN202210187026.6A patent/CN114539392B/zh active Active
-
2018
- 2018-01-25 PH PH12018500199A patent/PH12018500199A1/en unknown
- 2018-02-02 ZA ZA2018/00710A patent/ZA201800710B/en unknown
- 2018-03-25 IL IL258326A patent/IL258326B/en unknown
-
2020
- 2020-04-30 US US16/864,087 patent/US11390664B2/en active Active
- 2020-08-26 CY CY20201100795T patent/CY1123462T1/el unknown
-
2021
- 2021-04-14 JP JP2021068062A patent/JP7171809B2/ja active Active
-
2022
- 2022-07-18 US US17/867,466 patent/US12037381B2/en active Active
- 2022-11-02 JP JP2022175909A patent/JP2023011809A/ja not_active Withdrawn
-
2024
- 2024-05-01 JP JP2024074160A patent/JP2024097078A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL258326B (en) | Antibodies that neutralize the hepatitis b virus in potency and their uses | |
| IL283321A (en) | Antibodies against muc16 and their uses | |
| IL258284A (en) | Anti-Lag 3 antibodies and their uses | |
| IL255961B (en) | Anti-cd40 antibodies and uses thereof | |
| IL257263A (en) | Antibodies against angptl8 and their use | |
| ZA201800536B (en) | Il-8-binding antibodies and uses thereof | |
| HUE056243T2 (hu) | Emberi immunhiányt okozó vírust semlegesítõ ellenanyagok | |
| SG11201803474UA (en) | Vaccines against hepatitis b virus | |
| IL254534A0 (en) | Anti-ceacam6 antibodies and uses thereof | |
| IL254954A0 (en) | Anti-pacap antibodies and their uses | |
| PT3292154T (pt) | Anticorpos anti-her3 humano e seus usos | |
| IL249660B (en) | Methods for treating hepatitis b virus and hepatitis d virus infections | |
| LT3220947T (lt) | Antikūnai, galintys neutralizuoti pasiutligės virusą ir kitus lisavirusus bei jų panaudojimas | |
| IL267785A (en) | virus | |
| GB201503387D0 (en) | Anti-carbapenem antibodies and uses thereof | |
| SG10201913958QA (en) | Modulation of hepatitis b virus replication | |
| GB201702193D0 (en) | Hepatitis E virus vaccine | |
| GB201600382D0 (en) | Engineered virus | |
| GB201716047D0 (en) | Virus | |
| GB201708778D0 (en) | Virus and method | |
| GB201708779D0 (en) | Virus and method | |
| GB201600380D0 (en) | Modified virus | |
| GB201700259D0 (en) | Virus |